Ulcerative Colitis Clinical Trial
— TURN2Official title:
Transfer of Feces in Ulcerative Colitis 2; Improving Efficacy
The goal of this placebo-controlled randomised multicenter trial is to evaluate the efficacy and safety of anaerobic prepared donor fecal microbiota transplantation (FMT) compared to autologous FMT in patient with ulcerative colitis. Participants will receive 4 treatments with frozen FMT via both upper and lower gastro-intestinal route (infusion via duodenal tube and enemas). Donors are selected based on microbiota profile.
Status | Recruiting |
Enrollment | 76 |
Est. completion date | December 1, 2025 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Age =18 and <70 - Ability to give informed consent - Established ulcerative colitis with known involvement of the left colon according to the Lennard-Jones criteria - Partial mayo score of = 3 and calprotectin > 250 - Full Mayo score 5-9 - Endoscopic Mayo score of =2 in either the rectum or sigmoid upon screening sigmoidoscopy - Stable dose of thiopurines or , 5-ASA, or budesonide in preceding 8 weeks. - Stable dose of budesonide in preceding 2 weeks. - Prednisone use =15mg/day in preceding 2 weeks with a mandatory taper of 5 mg per week starting from week 4. - Women need to use reliable contraceptives during participation in the study - Alkaline phosphatase > 1.5 x ULN in the subgroup of PSC/UC patients. Exclusion Criteria: - Condition leading to profound immunosuppression - For example: HIV, infectious diseases leading to immunosuppression, bone marrow malignancies - Use of systemic chemotherapy - Child-Pugh B liver cirrhosis - Anti-TNFa treatment in preceding 2 months - Vedolizumab treatment in preceding 2 months - Tofacitinib treatment in preceding 2 months - Ustekinumab treatment in preceding 2 months - Cyclosporine treatment in preceding 4 weeks - Use of Methotrexate in preceding 2 months - Prednisolone dose > 15 mg/day in preceding 2 weeks - Use of topical therapy in preceding 2 weeks - Life expectancy < 12 months - Difficulty with swallowing - Use of systemic antibiotics in preceding 4 weeks - Use of probiotic treatment in preceding 4 weeks - Positive stool cultures for common enteric pathogens (Salmonella, Shigella, Yersinia, Campylobacter, enteropathogenic e coli) - Positive C. Difficile stool test - Positive dual faeces test for pathogenic parasites e.g. Dientamoeba histolytica, Giardia Lamblia, Dientamoeba fragilis, Blastocystis hominis only if microscopically many or very many blastocysts are seen. - Positive serological test for HIV - History of surgery: - presence of a pouch - presence of stoma - Known intra-abdominal fistula - Pregnancy or women who give breastfeeding - Vasopressive medication, icu stay - Signs of ileus, diminished passage - Allergy to macrogol or substituents, eg peanuts, shellfish - Known allergy to iv gadolinium in the subgroup of patients who would be scheduled for MRI liver - Crohn's disease - Subject who has any conditions that in the opinion of the investigator, would compromise the safety of the subject or the quality of the data and is an unsuitable candidate for the study |
Country | Name | City | State |
---|---|---|---|
Netherlands | Amsterdam University Medical Center | Amsterdam | Noord-Holland |
Lead Sponsor | Collaborator |
---|---|
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | UMC Utrecht, University Medical Center Groningen |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical and endoscopic remission | per adapted Mayo: stool frequency subscores (SFS) = 1, rectal bleeding subscore (RBS) =0 and endoscopic subscore = 1.
The adapted Mayo score has a minimum score of 0 and a maximum score of 9. The 3 subscores (SFS, RBS, and endoscopic subscore) have a minimum of 0 and a maximum score of 3. The adapted Mayo score does not include PGA (physician global assessment), in contrary to the full Mayo score. A higher score reflects worse outcome. |
week 8 | |
Secondary | Clinical response | Adapted Mayo: decrease from baseline = 2 points and = 30% plus a decrease in RBS = 1 or an absolute RBS = 1.
The adapted Mayo score has a minimum score of 0 and a maximum score of 9. The 3 subscores (SFS, RBS, and endoscopic subscore) have a minimum of 0 and a maximum score of 3. The adapted Mayo score does not include PGA (physician global assessment), in contrary to the full Mayo score. |
week 8 | |
Secondary | Endoscopic response, evaluated by sigmoidoscopy | •Proportion of patients with =1 point reduction in summed endoscopic Mayo score of both the rectum and sigmoid. | week 8 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |